{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:21:43Z","timestamp":1776824503118,"version":"3.51.2"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T00:00:00Z","timestamp":1461542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T00:00:00Z","timestamp":1461542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lasers Surg. Med."],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1002\/lsm.22531","type":"journal-article","created":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T13:15:25Z","timestamp":1461590125000},"page":"668-677","source":"Crossref","is-referenced-by-count":7,"title":["The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography"],"prefix":"10.1002","volume":"48","author":[{"given":"Kaveh","family":"Abri Aghdam","sequence":"first","affiliation":[{"name":"Department of Ophthalmology; University Eye Hospital, Hannover Medical School; Hannover Germany"},{"name":"Brain and Spinal Cord Injury Research Center; Neuroscience Institute; Tehran University of Medical Sciences; Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Seidensticker","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University Eye Hospital, Hannover Medical School; Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelie","family":"Pielen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University Eye Hospital, Hannover Medical School; Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Framme","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University Eye Hospital, Hannover Medical School; Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Junker","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University Eye Hospital, Hannover Medical School; Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,4,25]]},"reference":[{"key":"10.1002\/lsm.22531-BIB0001|lsm22531-cit-0001","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1001\/archopht.116.5.653","article-title":"Age-specific prevalence and causes of blindness and visual impairment in an older population: The Rotterdam Study","volume":"116","author":"Klaver","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1002\/lsm.22531-BIB0002|lsm22531-cit-0002","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jcp.22708","article-title":"Regulation of VEGF expression in human retinal cells by cytokines: Implications for the role of inflammation in age-related macular degeneration","volume":"227","author":"Nagineni","year":"2012","journal-title":"J Cell Physiol"},{"key":"10.1002\/lsm.22531-BIB0003|lsm22531-cit-0003","first-page":"343","article-title":"Profile of ranibizumab: Efficacy and safety for the treatment of wet age-related macular degeneration","volume":"8","author":"Chen","year":"2012","journal-title":"Ther Clin Risk Manag"},{"key":"10.1002\/lsm.22531-BIB0004|lsm22531-cit-0004","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40123-013-0015-2","article-title":"Aflibercept for the treatment of age-related macular degeneration","volume":"2","author":"Trichonas","year":"2013","journal-title":"Ophthalmol Ther"},{"key":"10.1002\/lsm.22531-BIB0005|lsm22531-cit-0005","first-page":"6","article-title":"Aflibercept approved for macular degeneration","volume":"69","author":"Traynor","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1002\/lsm.22531-BIB0006|lsm22531-cit-0006","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrd3700","article-title":"Aflibercept","volume":"11","author":"Stewart","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1002\/lsm.22531-BIB0007|lsm22531-cit-0007","first-page":"495","article-title":"Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration","volume":"7","author":"Thomas","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1002\/lsm.22531-BIB0008|lsm22531-cit-0008","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/bjo.2011.203893","article-title":"Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab","volume":"96","author":"Egh\u00f8j","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1002\/lsm.22531-BIB0009|lsm22531-cit-0009","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.ophtha.2008.07.007","article-title":"Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration","volume":"115","author":"Schaal","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1002\/lsm.22531-BIB0010|lsm22531-cit-0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bjophthalmol-2011-301236","article-title":"Loss of reactivity in intravitreal anti-VEGF therapy: Tachyphylaxis or tolerance","volume":"96","author":"Binder","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1002\/lsm.22531-BIB0011|lsm22531-cit-0011","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/IAE.0b013e3181a2c1c3","article-title":"Tachyphy\u00adlaxis after intravitreal bevacizumab for exudative age-related macular degeneration","volume":"29","author":"Forooghian","year":"2009","journal-title":"Retina"},{"key":"10.1002\/lsm.22531-BIB0012|lsm22531-cit-0012","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3928\/23258160-20130313-04","article-title":"SAVE (super-dose anti-VEGF) trial: 2.0\u2009mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results","volume":"44","author":"Wykoff","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1002\/lsm.22531-BIB0013|lsm22531-cit-0013","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/IAE.0b013e31828e8551","article-title":"Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration","volume":"33","author":"Kumar","year":"2013","journal-title":"Retina"},{"key":"10.1002\/lsm.22531-BIB0014|lsm22531-cit-0014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ajo.2013.03.030","article-title":"Conversion to aflibercept for chronic refractory or recurrent neovascular age related macular degeneration","volume":"156","author":"Yonekawa","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1002\/lsm.22531-BIB0015|lsm22531-cit-0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajo.2013.02.009","article-title":"Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors","volume":"156","author":"Ho","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1002\/lsm.22531-BIB0016|lsm22531-cit-0016","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1002\/lsm.22531-BIB0017|lsm22531-cit-0017","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3109\/02713683.2012.727521","article-title":"Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET\/CT","volume":"37","author":"Christoforidis","year":"2012","journal-title":"Curr Eye Res"},{"key":"10.1002\/lsm.22531-BIB0018|lsm22531-cit-0018","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/hep.24238","article-title":"Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice","volume":"53","author":"Van Steenkiste","year":"2011","journal-title":"Hepatology"},{"key":"10.1002\/lsm.22531-BIB0019|lsm22531-cit-0019","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1167\/iovs.09-4496","article-title":"Effects on choroidal neovascularization after anti-VEGF Upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography","volume":"51","author":"Framme","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1002\/lsm.22531-BIB0020|lsm22531-cit-0020","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00417-014-2589-3","article-title":"Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD","volume":"252","author":"Fassnacht-Riederle","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1002\/lsm.22531-BIB0021|lsm22531-cit-0021","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/eye.2014.101","article-title":"Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results","volume":"28","author":"Grewal","year":"2014","journal-title":"Eye (Lond)"},{"key":"10.1002\/lsm.22531-BIB0022|lsm22531-cit-0022","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1001\/archopht.122.5.710","article-title":"Morphometric analysis of angiograms of exudative lesions in age-related macular degeneration","volume":"122","author":"Ali","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1002\/lsm.22531-BIB0023|lsm22531-cit-0023","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1111\/aos.12681","article-title":"Initial improvements when converting eyes with treatment-resistant exudative AMD to aflibercept are substantially diminished after increasing treatment intervals from 4 to 8 weeks","volume":"93","author":"J\u00f8rstad","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1002\/lsm.22531-BIB0024|lsm22531-cit-0024","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000757","article-title":"Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results","author":"Aghdam","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"10.1002\/lsm.22531-BIB0025|lsm22531-cit-0025","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ajo.2008.05.032","article-title":"Enhanced depth imaging spectral-domain optical coherence tomography","volume":"146","author":"Spaide","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1002\/lsm.22531-BIB0026|lsm22531-cit-0026","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ajo.2007.06.014","article-title":"Optical coherence tomography identification of occult choroid neovascularization in age-related macular degeneration","volume":"144","author":"Coscas","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1002\/lsm.22531-BIB0027|lsm22531-cit-0027","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ajo.2005.02.042","article-title":"Occult chorioretinal anastomosis in age-related macular degeneration: A prospective study by optical coherence tomography","volume":"140","author":"Costa","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1002\/lsm.22531-BIB0028|lsm22531-cit-0028","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1088\/0031-9155\/40\/6\/001","article-title":"Optical properties of ocular fundus tissues: An in vitro study using the double-integrating-sphere technique and inverse Monte Carlo simulation","volume":"40","author":"Hammer","year":"1995","journal-title":"Phys Med Biol"},{"key":"10.1002\/lsm.22531-BIB0029|lsm22531-cit-0029","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1167\/iovs.12-9878","article-title":"En face enhanced depth imaging optical coherence tomography of fibrovascular pigment epithelium detachment","volume":"53","author":"Coscas","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Lasers in Surgery and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flsm.22531","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flsm.22531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/lsm.22531\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T15:25:30Z","timestamp":1625498730000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/lsm.22531"}},"subtitle":["AFLIBERCEPT AND CNV LESION SIZE"],"short-title":[],"issued":{"date-parts":[[2016,4,25]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,9]]}},"URL":"https:\/\/doi.org\/10.1002\/lsm.22531","archive":["Portico"],"relation":{},"ISSN":["0196-8092"],"issn-type":[{"value":"0196-8092","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4,25]]}}}